Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration

doi:10.3748/wjg.v30.i18.2387

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2044)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

1496

Sum=1533

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

140

Download

115

Sum=255

Publishing Process of This Article

Item

Count

Browse

Download

132

Sum=171

May 14, 2024 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. May 14, 2024; 30(18): 2387-2390
Published online May 14, 2024. doi: 10.3748/wjg.v30.i18.2387

Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration

Aleksandra Boldys, Lukasz Buldak

Aleksandra Boldys, Lukasz Buldak, Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia, Katowice 40-752, Poland

Author contributions: Boldys A and Buldak L wrote this manuscript; Boldys A outlined the subject. Both authors were involved in original manuscript preparation and revision.

Conflict-of-interest statement: The authors have nothing to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Lukasz Buldak, MD, PhD, Associate Professor, Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia, Medykow 18, Katowice 40-752, Poland. lbuldak@gmail.com

Received: December 28, 2023
Revised: April 7, 2024
Accepted: April 24, 2024
Published online: May 14, 2024
Processing time: 134 Days and 13.5 Hours

Core Tip

Core Tip: The transition from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a broader understanding of liver steatosis beyond obesity-related factors. Early recognition and diagnosis of MASLD are essential. Updated diagnostic protocols and exploration of novel therapeutic avenues focusing on metabolic dysregulation are critical for improving outcomes in MASLD management. Cross-disciplinary collaboration is key to addressing the complexities of this disease effectively.